Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Marc A. Dall'Era"'
Autor:
Marc A. Dall'Era, Kevin R. Loughlin, Daniel W. Lin, Brock O'Neil, Tanya B. Dorff, Karen E. Hoffman
Publikováno v:
Urologic oncology. 39(9)
Major changes in the field of prostate cancer over the last 25 years include the implementation of prostate specific antigen screening and the recognition that BRCA confers hereditary risk of prostate cancer. Quality of life and survivorship have dri
Autor:
Andrew J. Stephenson, Shahrokh F. Shariat, Simon Horenblas, Michael S. Cookson, Kamran Zargar-Shoshtari, Jonathan Aning, Yair Lotan, Andrew C. Thorpe, Peter C. Black, Homayoun Zargar, Nicholas J. Campain, Todd M. Morgan, Jeffrey S. Montgomery, Srikala S. Sridhar, Trinity J. Bivalacqua, Jonathan L. Wright, Laura Maria Krabbe, Anna J. Black, Cesar E. Ercole, Colin P.N. Dinney, Evan Y. Yu, Niels Jacobsen, Laura S. Mertens, Scott North, Bas W.G. van Rhijn, Jay B. Shah, Nikhil Vasdev, Evanguelos Xylinas, Siamak Daneshmand, Petros Grivas, Jo An Seah, Daniel A. Barocas, Marc A. Dall'Era, Jeff M. Holzbeierlein, Philippe E. Spiess, Maria Carmen Mir, Wassim Kassouf, John S. McGrath, Adrian Fairey, Joshua Griffin
Publikováno v:
Urologic Oncology: Seminars and Original Investigations, 38(1), 3.e17-3.e27. Elsevier Inc.
Black, A J, Zargar, H, Zargar-Shoshtari, K, Fairey, A S, Mertens, L S, Dinney, C P, Mir, M C, Krabbe, L M, Cookson, M S, Jacobsen, N E, Griffin, J, Montgomery, J S, Vasdev, N, Yu, E Y, Xylinas, E, Campain, N J, Kassouf, W, Dall'Era, M A, Seah, J A, Ercole, C E, Horenblas, S, McGrath, J S, Aning, J, Shariat, S F, Wright, J L, Thorpe, A C, Morgan, T M, Holzbeierlein, J M, Bivalacqua, T J, North, S, Barocas, D A, Lotan, Y, Grivas, P, Stephenson, A J, Shah, J B, van Rhijn, B W, Spiess, P E, Daneshmand, S, Sridhar, S S & Black, P C 2020, ' The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy ', Urologic Oncology: Seminars and Original Investigations, vol. 38, no. 1, pp. 3.e17-3.e27 . https://doi.org/10.1016/j.urolonc.2019.09.023
Black, A J, Zargar, H, Zargar-Shoshtari, K, Fairey, A S, Mertens, L S, Dinney, C P, Mir, M C, Krabbe, L M, Cookson, M S, Jacobsen, N E, Griffin, J, Montgomery, J S, Vasdev, N, Yu, E Y, Xylinas, E, Campain, N J, Kassouf, W, Dall'Era, M A, Seah, J A, Ercole, C E, Horenblas, S, McGrath, J S, Aning, J, Shariat, S F, Wright, J L, Thorpe, A C, Morgan, T M, Holzbeierlein, J M, Bivalacqua, T J, North, S, Barocas, D A, Lotan, Y, Grivas, P, Stephenson, A J, Shah, J B, van Rhijn, B W, Spiess, P E, Daneshmand, S, Sridhar, S S & Black, P C 2020, ' The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy ', Urologic Oncology: Seminars and Original Investigations, vol. 38, no. 1, pp. 3.e17-3.e27 . https://doi.org/10.1016/j.urolonc.2019.09.023
Introduction The neutrophil-to-lymphocyte ratio (NLR) is an attractive marker because it is derived from routine bloodwork. NLR has shown promise as a prognostic factor in muscle invasive bladder cancer (MIBC) but its value in patients receiving neoa